Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
More Pharma Arts Reporting, Please
July 20, 2015
| A version of this story appeared in
Volume 93, Issue 29
I read “Schooled in the Pharma Arts” with interest (C&EN, May 25, page 12). However, only Waisman Biomanufacturing is highlighted as a contract manufacturing organization making gene therapy drugs.
I am surprised by how many medical centers and universities have cooperated to create small Good Manufacturing Practices (GMP) production areas to make viral-based gene therapy drugs within hospitals. These facilities are establishing new methods to make and deliver genes to clinical trials with a small number of patients. Have you previously reported on this group of GMP facilities?
Bob Steininger
Cambridge, Mass.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter